- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02446600
Test af brugen af et enkelt lægemiddel (Olaparib) eller kombinationen af to lægemidler (Cediranib og Olaparib) sammenlignet med den sædvanlige kemoterapi til kvinder med platinfølsom ovarie-, æggeleder- eller primær peritonealkræft
Et fase III-studie, der sammenligner enkeltmiddel olaparib eller kombinationen af cediranib og olaparib med standard platinbaseret kemoterapi hos kvinder med tilbagevendende platinfølsom ovarie-, æggeleder- eller primær peritonealcancer
This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Studieoversigt
Status
Betingelser
- Tilbagevendende æggelederkarcinom
- Tilbagevendende ovariekarcinom
- Tilbagevendende primært peritonealt karcinom
- Ovarial seromucinøst karcinom
- Ovarialt udifferentieret karcinom
- Ovarial klarcellet adenokarcinom
- Overgangscellekarcinom i æggelederen
- Ovarialt overgangscellekarcinom
- Klarcellet adenokarcinom i æggelederen
- Æggelederudifferentieret karcinom
- Tilbagevendende ovarieendometrioid adenokarcinom
- Ovarie endometrioid tumor
- Serøs ovarietumor
Intervention / Behandling
- Medicin: Carboplatin
- Medicin: Paclitaxel
- Andet: Laboratory Biomarker Analysis
- Andet: Quality-of-Life Assessment
- Procedure: Biospecimen Collection
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Procedure: Echocardiography Test
- Procedure: Multigated Acquisition Scan
- Andet: Pharmacological Study
- Medicin: Gemcitabine Hydrochloride
- Medicin: Cediranib Maleate
- Medicin: Olaparib
- Medicin: Gemcitabine
- Medicin: Pegylated Liposomal Doxorubicin Hydrochloride
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. Assess the efficacy of either single agent olaparib or the combination of cediranib (cediranib maleate) and olaparib, as measured by progression free survival (PFS), as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
SECONDARY OBJECTIVES:
I. Assess the efficacy of single agent olaparib or the combination of cediranib and olaparib, as measured by response rate and overall survival as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
II. Assess the efficacy of single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, in women with or without deleterious germline breast cancer (BRCA) mutations (gBRCAmt) in the setting of recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer.
III. Assess the effect on disease-related symptoms (DRS) as measured by the 9-item DRS-P subscale of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18), of single agent olaparib or cediranib and olaparib, compared to standard platinum-based chemotherapy, in the setting of recurrent platinum sensitive ovarian, primary peritoneal or fallopian tube cancer.
IV. Assess the efficacy of single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, in women with or without homologous repair deficiencies as measured by BROCA in the setting of recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer.
V. To assess changes in the number of circulating endothelial cells (CECs) following three days of treatment with olaparib, combination olaparib/cediranib, or standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer.
VI. To assess whether change in the number of circulating endothelial cells (CECs) following three days of treatment with olaparib, combination olaparib/cediranib, or standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer is prognostic for PFS.
VII. To develop a profile from a panel of angiogenic biomarkers in women with recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer which is associated with PFS, and then validate the predictive value of this biomarker profile.
EXPLORATORY OBJECTIVES:
I. To assess the time from randomization to the first non-study, anti-cancer therapy, surgery or death (TFST) for single-agent olaparib or combination cediranib and olaparib relative to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
II. To assess the time from randomization to the second non-study, anti-cancer therapy, surgery or death (TSST) for single-agent olaparib or combination cediranib and olaparib relative to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
III. Assess the effect on secondary measures of quality of life, as assessed by the treatment side effects (TSE) and function/well-being (F/WB) subscales of the NFOSI-18, sensory neuropathy as measured by the FACT/Gynecologic Oncology Group-Neurotoxicity version 4 (GOG-Ntx-4), and health utility as measured by the Euro Quality of Life-5 Dimension (EQ-5D), of single agent olaparib or cediranib and olaparib, compared to standard platinum-based chemotherapy, in the setting of recurrent platinum sensitive ovarian, primary peritoneal or fallopian tube cancer.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients may be treated with one of the three regimens per investigator discretion.
REGIMEN I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30-60 minutes and on day 1. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) as well as blood sample collection throughout the trial.
REGIMEN II: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 for at least 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
REGIMEN III: Patients receive pegylated liposomal doxorubicin hydrochloride IV and carboplatin IV over 30-60 minutes and on day 1. Treatment repeats every 28 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
ARM II: Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
ARM III: Patients receive olaparib PO BID and cediranib maleate PO once daily (QD). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Hospital and Cancer Center-General Campus
-
Sault Ste. Marie, Ontario, Canada, P6B 0A8
- Algoma District Cancer Program Sault Area Hospital
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
Montreal, Quebec, Canada, H2X 3E4
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
Montreal, Quebec, Canada, H1T 2M4
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
Québec, Quebec, Canada, G1R 2J6
- CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Forenede Stater, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
Alaska
-
Anchorage, Alaska, Forenede Stater, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Forenede Stater, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85704
- Arizona Oncology Associates-West Orange Grove
-
Tucson, Arizona, Forenede Stater, 85710
- Arizona Oncology Associates-Wilmot
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Arroyo Grande, California, Forenede Stater, 93420
- PCR Oncology
-
Carmichael, California, Forenede Stater, 95608
- Mercy San Juan Medical Center
-
Greenbrae, California, Forenede Stater, 94904
- Marin Cancer Care Inc
-
La Jolla, California, Forenede Stater, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Forenede Stater, 90048
- Cedars-Sinai Medical Center
-
Mountain View, California, Forenede Stater, 94040
- Palo Alto Medical Foundation-Camino Division
-
Mountain View, California, Forenede Stater, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Oakland, California, Forenede Stater, 94611
- Kaiser Permanente-Oakland
-
Palo Alto, California, Forenede Stater, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Forenede Stater, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Forenede Stater, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Forenede Stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Forenede Stater, 95825
- Kaiser Permanente Sacramento Medical Center
-
Sacramento, California, Forenede Stater, 95816
- Mercy Cancer Center - Sacramento
-
San Francisco, California, Forenede Stater, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Forenede Stater, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Forenede Stater, 94115
- California Pacific Medical Center-Pacific Campus
-
San Luis Obispo, California, Forenede Stater, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Clara, California, Forenede Stater, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Cruz, California, Forenede Stater, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Forenede Stater, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Forenede Stater, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Forenede Stater, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Forenede Stater, 94596
- Kaiser Permanente-Walnut Creek
-
Woodland, California, Forenede Stater, 95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Forenede Stater, 80045
- UCHealth University of Colorado Hospital
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forenede Stater, 80909
- UCHealth Memorial Hospital Central
-
Denver, Colorado, Forenede Stater, 80205
- Kaiser Permanente-Franklin
-
Denver, Colorado, Forenede Stater, 80220
- Rocky Mountain Cancer Centers-Rose
-
Fort Collins, Colorado, Forenede Stater, 80524
- Poudre Valley Hospital
-
Lafayette, Colorado, Forenede Stater, 80026
- Kaiser Permanente-Rock Creek
-
Littleton, Colorado, Forenede Stater, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Forenede Stater, 80124
- Kaiser Permanente-Lone Tree
-
Lone Tree, Colorado, Forenede Stater, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Wheat Ridge, Colorado, Forenede Stater, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Fairfield, Connecticut, Forenede Stater, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Hartford, Connecticut, Forenede Stater, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, Forenede Stater, 06102
- Hartford Hospital
-
Middletown, Connecticut, Forenede Stater, 06457
- Middlesex Hospital
-
New Britain, Connecticut, Forenede Stater, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Forenede Stater, 06520
- Yale University
-
Torrington, Connecticut, Forenede Stater, 06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull, Connecticut, Forenede Stater, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
-
Delaware
-
Newark, Delaware, Forenede Stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forenede Stater, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Forenede Stater, 19971
- Beebe Health Campus
-
Seaford, Delaware, Forenede Stater, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
- UF Health Cancer Institute - Gainesville
-
-
Georgia
-
Athens, Georgia, Forenede Stater, 30607
- University Cancer and Blood Center LLC
-
Atlanta, Georgia, Forenede Stater, 30309
- Piedmont Hospital
-
Atlanta, Georgia, Forenede Stater, 30342
- Northside Hospital
-
Decatur, Georgia, Forenede Stater, 30033
- Emory Decatur Hospital
-
Macon, Georgia, Forenede Stater, 31201
- Atrium Health Navicent
-
Savannah, Georgia, Forenede Stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Forenede Stater, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Forenede Stater, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forenede Stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Forenede Stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forenede Stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
-
Illinois
-
Aurora, Illinois, Forenede Stater, 60504
- Rush-Copley Medical Center
-
Bloomington, Illinois, Forenede Stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forenede Stater, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Forenede Stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forenede Stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Chicago, Illinois, Forenede Stater, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Forenede Stater, 60657
- UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital
-
Chicago, Illinois, Forenede Stater, 60612
- Rush MD Anderson Cancer Center
-
Decatur, Illinois, Forenede Stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Forenede Stater, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Forenede Stater, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Forenede Stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Forenede Stater, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Forenede Stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forenede Stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Forenede Stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Hinsdale, Illinois, Forenede Stater, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee, Illinois, Forenede Stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Forenede Stater, 61455
- Illinois CancerCare-Macomb
-
O'Fallon, Illinois, Forenede Stater, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Forenede Stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Forenede Stater, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Forenede Stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forenede Stater, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forenede Stater, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Forenede Stater, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forenede Stater, 62781
- Springfield Memorial Hospital
-
Warrenville, Illinois, Forenede Stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Clive, Iowa, Forenede Stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forenede Stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Forenede Stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- University of Kansas Cancer Center
-
Pittsburg, Kansas, Forenede Stater, 66762
- Mercy Hospital Pittsburg
-
Topeka, Kansas, Forenede Stater, 66606
- Cotton O'Neil Cancer Center / Stormont Vail Health
-
Wichita, Kansas, Forenede Stater, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Forenede Stater, 67208
- Associates In Womens Health
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Forenede Stater, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, Forenede Stater, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, Forenede Stater, 40207
- Norton Suburban Hospital and Medical Campus
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Forenede Stater, 70817
- Woman's Hospital
-
Covington, Louisiana, Forenede Stater, 70433
- Women's Cancer Care-Covington
-
New Orleans, Louisiana, Forenede Stater, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Forenede Stater, 04401
- Eastern Maine Medical Center
-
Brewer, Maine, Forenede Stater, 04412
- Lafayette Family Cancer Center-EMMC
-
Scarborough, Maine, Forenede Stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Forenede Stater, 21204
- Greater Baltimore Medical Center
-
Easton, Maryland, Forenede Stater, 21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Forenede Stater, 02111
- Tufts Medical Center
-
Burlington, Massachusetts, Forenede Stater, 01805
- Lahey Clinic
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brownstown, Michigan, Forenede Stater, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, Forenede Stater, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Detroit, Michigan, Forenede Stater, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Forenede Stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
Escanaba, Michigan, Forenede Stater, 49829
- OSF Saint Francis Hospital and Medical Group
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Forenede Stater, 48503
- Hurley Medical Center
-
Flint, Michigan, Forenede Stater, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Forenede Stater, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Forenede Stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Manistique, Michigan, Forenede Stater, 49854
- Schoolcraft Memorial Hospital
-
Pontiac, Michigan, Forenede Stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Southfield, Michigan, Forenede Stater, 48075
- Henry Ford Health Providence Southfield Hospital
-
Traverse City, Michigan, Forenede Stater, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, Forenede Stater, 48322
- Henry Ford West Bloomfield Hospital
-
-
Minnesota
-
Bemidji, Minnesota, Forenede Stater, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Forenede Stater, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Forenede Stater, 55433
- Mercy Hospital
-
Edina, Minnesota, Forenede Stater, 55435
- Fairview Southdale Hospital
-
Mankato, Minnesota, Forenede Stater, 56001
- Mayo Clinic Health Systems-Mankato
-
Maple Grove, Minnesota, Forenede Stater, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Forenede Stater, 55109
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Forenede Stater, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Forenede Stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Forenede Stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forenede Stater, 55102
- United Hospital
-
Shakopee, Minnesota, Forenede Stater, 55379
- Saint Francis Regional Medical Center
-
Woodbury, Minnesota, Forenede Stater, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- University of Mississippi Medical Center
-
Jackson, Mississippi, Forenede Stater, 39216
- Saint Dominic-Jackson Memorial Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Saint Francis Medical Center
-
Joplin, Missouri, Forenede Stater, 64804
- Mercy Hospital Joplin
-
Springfield, Missouri, Forenede Stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forenede Stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forenede Stater, 63110
- Barnes-Jewish Hospital
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
-
Montana
-
Billings, Montana, Forenede Stater, 59101
- Billings Clinic Cancer Center
-
Great Falls, Montana, Forenede Stater, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Forenede Stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forenede Stater, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Forenede Stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Forenede Stater, 68847
- CHI Health Good Samaritan
-
Omaha, Nebraska, Forenede Stater, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Forenede Stater, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Forenede Stater, 68130
- Alegent Health Lakeside Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89106
- Women's Cancer Center of Nevada
-
-
New Hampshire
-
Dover, New Hampshire, Forenede Stater, 03820
- Wentworth-Douglass Hospital
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Nashua, New Hampshire, Forenede Stater, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Basking Ridge, New Jersey, Forenede Stater, 07920
- Memorial Sloan Kettering Basking Ridge
-
Camden, New Jersey, Forenede Stater, 08103
- Cooper Hospital University Medical Center
-
Englewood, New Jersey, Forenede Stater, 07631
- Englewood Hospital and Medical Center
-
Voorhees Township, New Jersey, Forenede Stater, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Forenede Stater, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Forenede Stater, 88011
- Memorial Medical Center-Las Cruces
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11203
- State University of New York Downstate Medical Center
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
Commack, New York, Forenede Stater, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Forenede Stater, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forenede Stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Forenede Stater, 14642
- University of Rochester
-
The Bronx, New York, Forenede Stater, 10461
- Montefiore Medical Center-Einstein Campus
-
Uniondale, New York, Forenede Stater, 11553
- Memorial Sloan Kettering Nassau
-
White Plains, New York, Forenede Stater, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham, North Carolina, Forenede Stater, 27710
- Duke University Medical Center
-
Goldsboro, North Carolina, Forenede Stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville, North Carolina, Forenede Stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Pinehurst, North Carolina, Forenede Stater, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Raleigh, North Carolina, Forenede Stater, 27609
- Duke Cancer Center Raleigh
-
Wilmington, North Carolina, Forenede Stater, 28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Forenede Stater, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Broadway Medical Center
-
Minot, North Dakota, Forenede Stater, 58701
- Trinity Cancer Care Center
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44307
- Cleveland Clinic Akron General
-
Akron, Ohio, Forenede Stater, 44304
- Summa Health System - Akron Campus
-
Beachwood, Ohio, Forenede Stater, 44122
- UHHS-Chagrin Highlands Medical Center
-
Cincinnati, Ohio, Forenede Stater, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati, Ohio, Forenede Stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Forenede Stater, 45247
- TriHealth Cancer Institute-Westside
-
Cleveland, Ohio, Forenede Stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forenede Stater, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forenede Stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forenede Stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forenede Stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forenede Stater, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Forenede Stater, 43214
- Columbus Oncology and Hematology Associates Inc
-
Dayton, Ohio, Forenede Stater, 45405
- Grandview Hospital
-
Findlay, Ohio, Forenede Stater, 45840
- Orion Cancer Care
-
Mayfield Heights, Ohio, Forenede Stater, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Forenede Stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Sylvania, Ohio, Forenede Stater, 43560
- ProMedica Flower Hospital
-
Toledo, Ohio, Forenede Stater, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Wadsworth, Ohio, Forenede Stater, 44281
- University Hospitals Sharon Health Center
-
Westlake, Ohio, Forenede Stater, 44145
- UHHS-Westlake Medical Center
-
Wright-Patterson Air Force Base, Ohio, Forenede Stater, 45433
- Wright-Patterson Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forenede Stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, Forenede Stater, 97701
- Saint Charles Health System
-
Eugene, Oregon, Forenede Stater, 97401
- Willamette Valley Cancer Center
-
Gresham, Oregon, Forenede Stater, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Forenede Stater, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Forenede Stater, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, Forenede Stater, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Abington, Pennsylvania, Forenede Stater, 19001
- Jefferson Abington Hospital
-
Bethlehem, Pennsylvania, Forenede Stater, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Danville, Pennsylvania, Forenede Stater, 17822
- Geisinger Medical Center
-
Ephrata, Pennsylvania, Forenede Stater, 17522
- Ephrata Cancer Center
-
Gettysburg, Pennsylvania, Forenede Stater, 17325
- Adams Cancer Center
-
Lancaster, Pennsylvania, Forenede Stater, 17602
- Lancaster General Hospital
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- UPMC Hillman Cancer Center
-
Sayre, Pennsylvania, Forenede Stater, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
Selinsgrove, Pennsylvania, Forenede Stater, 17870
- Geisinger Medical Oncology-Selinsgrove
-
West Reading, Pennsylvania, Forenede Stater, 19611
- Reading Hospital
-
Williamsport, Pennsylvania, Forenede Stater, 17701
- UPMC Susquehanna
-
York, Pennsylvania, Forenede Stater, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Anderson, South Carolina, Forenede Stater, 29621
- AnMed Health Cancer Center
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
Gaffney, South Carolina, Forenede Stater, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forenede Stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forenede Stater, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Forenede Stater, 29651
- Gibbs Cancer Center-Pelham
-
Hilton Head Island, South Carolina, Forenede Stater, 29926-3827
- South Carolina Cancer Specialists PC
-
Spartanburg, South Carolina, Forenede Stater, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Forenede Stater, 29379
- SMC Center for Hematology Oncology Union
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Johnson City, Tennessee, Forenede Stater, 37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport, Tennessee, Forenede Stater, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Forenede Stater, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Knoxville, Tennessee, Forenede Stater, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Forenede Stater, 37932
- Covenant Health Cancer Centers - West
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Austin, Texas, Forenede Stater, 78731
- Texas Oncology - Central Austin Cancer Center
-
Austin, Texas, Forenede Stater, 78745
- Texas Oncology - South Austin Cancer Center
-
Bedford, Texas, Forenede Stater, 76022
- Texas Oncology Bedford
-
Dallas, Texas, Forenede Stater, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Forenede Stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Fort Worth, Texas, Forenede Stater, 76104
- Texas Oncology - Fort Worth Cancer Center
-
Houston, Texas, Forenede Stater, 77030
- Houston Methodist Hospital
-
Houston, Texas, Forenede Stater, 77070
- Methodist Willowbrook Hospital
-
Sugar Land, Texas, Forenede Stater, 77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, Forenede Stater, 77380
- Texas Oncology-The Woodlands
-
-
Utah
-
Murray, Utah, Forenede Stater, 84107
- Intermountain Medical Center
-
Salt Lake City, Utah, Forenede Stater, 84106
- Utah Cancer Specialists-Salt Lake City
-
St. George, Utah, Forenede Stater, 84770
- Saint George Regional Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Kennewick, Washington, Forenede Stater, 99336
- Kadlec Clinic Hematology and Oncology
-
Mount Vernon, Washington, Forenede Stater, 98274
- Skagit Valley Hospital
-
Mount Vernon, Washington, Forenede Stater, 98274
- Skagit Regional Health Cancer Care Center
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Forenede Stater, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Forenede Stater, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Forenede Stater, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Forenede Stater, 98133
- University of Washington Medical Center - Northwest
-
Seattle, Washington, Forenede Stater, 98133
- Women's Cancer Center of Seattle
-
Vancouver, Washington, Forenede Stater, 98686
- Legacy Salmon Creek Hospital
-
Wenatchee, Washington, Forenede Stater, 98801
- Wenatchee Valley Hospital and Clinics
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Huntington, West Virginia, Forenede Stater, 25701
- Edwards Comprehensive Cancer Center
-
-
Wisconsin
-
Chippewa Falls, Wisconsin, Forenede Stater, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Marshfield Clinic Cancer Center at Sacred Heart
-
Green Bay, Wisconsin, Forenede Stater, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Forenede Stater, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Gundersen Lutheran Medical Center
-
Ladysmith, Wisconsin, Forenede Stater, 54848
- Marshfield Medical Center - Ladysmith
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Forenede Stater, 54143
- Saint Vincent Hospital Cancer Center at Marinette
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Forenede Stater, 53149
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Forenede Stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oconto Falls, Wisconsin, Forenede Stater, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Stevens Point, Wisconsin, Forenede Stater, 54481
- Aspirus Cancer Care - Stevens Point
-
Sturgeon Bay, Wisconsin, Forenede Stater, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Waukesha, Wisconsin, Forenede Stater, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Forenede Stater, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Forenede Stater, 54401
- Marshfield Clinic-Wausau Center
-
Weston, Wisconsin, Forenede Stater, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Forenede Stater, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
-
-
-
Saitama, Japan, 350-1298
- Saitama Medical University International Medical Center
-
Tokyo, Japan, 104 0045
- National Cancer Center Hospital
-
-
Iwate
-
Shiwa-gun, Iwate, Japan, 028-3695
- Iwate Medical University Hospital
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japan, 890-8760
- Kagoshima City Hospital
-
-
Tokyo
-
Koto-ku, Tokyo, Japan, 135-8550
- The Cancer Institute Hospital Of JFCR
-
-
-
-
-
Seoul, Sydkorea, 110-744
- Seoul National University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patients must have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers; patients with other (clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma) high-risk histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory; Note: Due to the long acceptance of germline BRCA testing through Myriad, Myriad testing will be accepted; if testing for germline BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germline deleterious BRCA1 or BRCA2 mutation or BRCA rearrangement is required; please collect a copy of Myriad or other BRCA mutational analysis (positive or VUS or negative) reports
- Platinum-sensitive disease defined as no clinical or radiographic evidence of disease recurrence for > 6 months (or 182 days) after last receipt of platinum-based therapy
- Patients must have had a complete clinical response to their prior line of platinum therapy and cannot have had progression through prior platinum-based therapy
-
Patients must have signed an approved informed consent and authorization permitting release of personal health information
-
Patients must have evaluable disease - defined as one of the following:
- Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease OR
- Evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related) AND a cancer antigen 125 (CA125) that has doubled from the post-treatment nadir and is also greater than 2 times upper limit of normal (ULN)
-
Prior therapy:
- Prior chemotherapy must have included a first-line platinum-based regimen with or without intravenous consolidation chemotherapy
- Patients may have received an unlimited number of platinum-based therapies in the recurrent setting
- Patients may have received up to 1 non-platinum-based line of therapy in the recurrent setting; prior hormonal therapy will not be considered to count as this non-platinum-based line
- Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed
- Patients may not have previously received a poly adenosine diphosphate (ADP) ribose polymerase (PARP)-inhibitor
- Prior hormonal-based therapy for ovarian, primary peritoneal, or fallopian tube cancer is acceptable
-
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Karnofsky >= 60%)
-
Absolute neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Hemoglobin >= 10 g/dL
-
Creatinine =< the institutional upper limit of normal (ULN) OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
Urine protein: creatinine ratio (UPC) of =< 1 or less than or equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with >= 2+ proteinuria on dipstick must also have a 24 hour urine collection demonstrating =< 500 mg over 24 hours
-
Total bilirubin =< 1.5 x the institutional ULN
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 times institutional ULN
-
Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE); patients with long-standing stable grade 2 neuropathy may be considered after discussion with the overall principal investigator (PI), but may not receive carboplatin and paclitaxel as the reference regimen, if randomized to that arm
-
Patients must be able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
-
Patients must have adequately controlled blood pressure (BP), with a BP no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of three antihypertensive medications; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or blood pressure specialist for management of blood pressure while on protocol
-
Patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to Arm III
-
Cediranib has been shown to terminate fetal development in the rat, as expected for a process dependent on VEGF signaling; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after cediranib discontinuation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
-
Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid stimulating hormone (TSH) within normal limits
-
Age >= 18
Exclusion Criteria:
-
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions
-
Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
-
Patients may not be receiving any medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)
-
Patients may not have received prior treatment affecting the vascular endothelial growth factor (VEGF) pathway (including, but not limited to thalidomide, sunitinib, pazopanib, sorafenib, and nintedanib); bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowed
-
Patients may not have previously received a PARP inhibitor
-
CA-125 only disease without RECIST 1.1 measurable or otherwise evaluable disease
-
Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on CT or MRI scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events; screening imaging to rule out brain metastases is not required for screening, but should be performed prior to study enrollment if clinically indicated; patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study drug
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
-
Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; strong inhibitors and inducers of UGT/PgP should be used with caution
-
History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula
-
History of intra-abdominal abscess within the past 3 months
-
Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs
-
Dependency on intravenous (IV) hydration or total parenteral nutrition (TPN)
-
Any concomitant or prior invasive malignancies with the following curatively treated exceptions:
- Treated limited stage basal cell or squamous cell carcinoma of the skin
- Carcinoma in situ of the breast or cervix
- Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions
- Prior cancer treated with a curative intent with no evidence of recurrent disease 3 years following diagnosis and judged by the investigator to be at low risk of recurrence
-
Patients with any of the following:
- History of myocardial infarction within six months
- Unstable angina
- Resting electrocardiogram (ECG) with clinically significant abnormal findings
- New York Heart Association (NYHA) classification of III or IV
-
If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines
-
Patients with the following risk factors should have a baseline cardiac function assessment:
- Prior treatment with anthracyclines
- Prior treatment with trastuzumab
- Prior central thoracic radiation therapy (RT), including RT to the heart
- History of myocardial infarction within 6 to 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)
- Prior history of impaired cardiac function
-
-
History of stroke or transient ischemic attack within six months
-
Any prior history of hypertensive crisis or hypertensive encephalopathy
-
Clinically significant peripheral vascular disease or vascular disease (including aortic aneurysm or aortic dissection)
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
-
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements
-
Pregnant women are excluded from this study because cediranib and olaparib are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with cediranib and olaparib, breastfeeding should be discontinued if the mother is treated with cediranib or olaparib; these potential risks may also apply to other agents used in this study
-
Known HIV-positive individuals are ineligible because of the potential for pharmacokinetic interactions with cediranib or olaparib; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy
-
Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments
-
No features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
-
No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm I (platinum-based chemotherapy)
See detailed description. |
Given IV
Andre navne:
Given IV
Andre navne:
Correlative studies Ancillary studies
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo ECHO
Andre navne:
Undergo MUGA
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
|
|
Eksperimentel: Arm II (olaparib)
Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT or MRI as well as blood sample collection throughout the trial. |
Correlative studies Ancillary studies
Andre navne:
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo ECHO
Andre navne:
Undergo MUGA
Andre navne:
Correlative studies Given PO
Andre navne:
|
|
Eksperimentel: Arm III (olaparib, cediranib maleate)
Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection throughout the trial. |
Correlative studies Ancillary studies
Andre navne:
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo ECHO
Andre navne:
Undergo MUGA
Andre navne:
Correlative studies Given PO
Andre navne:
Given PO
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression Free Survival Determined Using Response Evaluation Criteria in Solid Tumors Version 1.1 Criteria
Tidsramme: The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. An average of approximately 10 months.
|
Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last follow-up were censored on the date of last CT Scan, or the CT Scan date prior to two missed assessments. Japanese cohort not included in progression free survival analysis, only included in toxicity assessments. |
The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. An average of approximately 10 months.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival
Tidsramme: Approximately 30 months
|
Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact. Japanese cohort not included in overall survival analysis, the cohort was only included in toxicity assessments. |
Approximately 30 months
|
|
Frequency and Severity of Adverse Effects
Tidsramme: During treatment period and up to 100 days after stopping the study treatment, up to 39 months.
|
Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy, by Preferred term with incidence rate greater than 5%. |
During treatment period and up to 100 days after stopping the study treatment, up to 39 months.
|
|
Patient Reported Scores of Disease-related Symptoms as Measured by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 Disease-Related Symptom-Physical
Tidsramme: Prior to cycle 1, week 12, week 24, week 36, week 48, week 60, week 72, week 84, week 96 and 108 weeks after starting treatment
|
Disease-related physical symptoms were measured by the Disease-Related Symptom-Physical (DRS-P) subscale of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NCCN/FOSI-18). The DRS-P subscale is composed of 9 items. For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The DRS-P score ranges 0-36 with a larger score suggesting better QOL (Quality of Life) or less symptoms. This analysis did not include the Japanese cohort. |
Prior to cycle 1, week 12, week 24, week 36, week 48, week 60, week 72, week 84, week 96 and 108 weeks after starting treatment
|
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Tid fra randomisering til det første ikke-studie, anti-kræftbehandling eller død
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
Tid fra randomisering til anden ikke-undersøgelse, anti-kræftbehandling eller død
Tidsramme: Op til 5 år
|
Op til 5 år
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Joyce F Liu, NRG Oncology
Publikationer og nyttige links
Generelle publikationer
- Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
- Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 Jul 1;40(19):2138-2147. doi: 10.1200/JCO.21.02011. Epub 2022 Mar 15.
- Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Kønssygdomme, kvindelige
- Neoplasmer i endokrine kirtler
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Æggeledersygdomme
- Ovariale neoplasmer
- Æggelederneoplasmer
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Kulhydrater
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glycosider
- Koordinationskomplekser
- Taxoider
- Cyclodecanes
- Diterpenes
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Sundhedsøkonomi og organisationer
- Kemiteknikker, analytisk
- Spektrumanalyse
- Anthracycliner
- Naphthacenes
- Aminoglycosider
- Daunorubicin
- Økonomi
- Gemcitabin
- Carboplatin
- Doxorubicin
- Paclitaxel
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Liposomal doxorubicin
- Olaparib
- Cediranib
- Skatter
Andre undersøgelses-id-numre
- NCI-2015-00606
- U10CA180868 (U.S. NIH-bevilling/kontrakt)
- NCI-2015-00606 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- s16-01480
- NRG-GY004 (Anden identifikator: CTEP)
- NRG-GY004
- NRG-GY004 (Anden identifikator: NRG Oncology)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .